Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 6/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669787 | 0.82 | HSP90AA1 (0.39) | HSP90AA1NPC1RAB9AGABRA1GABRG2 | |
| SCHEMBL32669919 | 0.80 | PDK1 (0.37) | HSP90AA1NPC1RAB9ASCN9APDK1 | |
| SCHEMBL32669921 | 0.79 | SCN9A (0.45) | HSP90AA1NPC1RAB9ASCN9A | |
| SCHEMBL9653677 | 0.74 | GABRA1 (0.55) | NPC1RAB9AGABRA1GABRG2GABRB3 | |
| SCHEMBL9653689 | 0.74 | ALDH1A1 (0.47) | RAB9AGABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL9653681 | 0.74 | ALDH1A1 (0.47) | RAB9AGABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL9653670 | 0.74 | GABRA1 (0.55) | NPC1RAB9AGABRA1GABRG2GABRB3 | |
| SCHEMBL9653267 | 0.74 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL9653262 | 0.74 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL9652085 | 0.73 | POLB (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | HSP90AA1 2632/4885COMT 52/4885FTO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.